-
Rubio touts US power, calls on Europe to emerge from 'slumber'
-
New Zealand fly-half Mo'unga ruled out of Australia Tests
-
Trump says 'we don't think' Russian plague is bio-weapon
-
Protests in major Turkish city after mayor defects to Erdogan party
-
Five children among 26 killed in Ukraine after Russian strikes
-
Climate change strips island's title of largest penguin colony: study
-
Man City should 'accept' punishment for rule breaches, says Lineker
-
Rubio says West must choose between national power or decline
-
US woman who survived botched execution is awake and speaking
-
Russia's plague scare: What we know
-
From 1800s to modern pharma: a Nobel-winning chemistry quest
-
French luxury giant to fund redevelopment of two Paris streets: city hall
-
Southampton boss Eckert given suspended ban over 'Spygate'
-
Trump wants to turn Florida golf course into presidential retreat
-
Russia warns of 'false' information as second plague case reported
-
Mayor of Turkish opposition stronghold defects to Erdogan party
-
IEA ready to release more oil reserves if necessary
-
Children among heavy casualties in Ukraine after Russian strikes
-
HSBC 'consults' over UK unit job cuts amid AI adoption
-
Court orders German ex-spy chief kept in jail after spying, treason arrest
-
UK court quashes five ex-traders' Libor rate rigging convictions
-
Guinea caps bottled water prices after sachets banned
-
XM Receives “Global Customer Experience Leader Award 2026” at the TrustFinance Performance Awards
-
Spared, married, hanged: the last weeks of Iranian protester Alireza Sepahi
-
Stocks slide as oil climbs on Mideast flareup
-
Nobel physics winner's pride at pioneering AI role
-
Heavy casualties in Ukraine after Russian strikes
-
IMF preparing El Nino assistance, concerned about AI bubble burst: chief to AFP
-
French wine harvest set to hit historic low
-
West must embrace 'national power' or face decline: Rubio
-
Kyiv 'cannot agree' to EU membership limiting food exports: minister
-
Shell refining margins reach record highs as wars hit supply
-
Arteta targets more Arsenal glory after signing new deal until 2030
-
Former Spain, Barca winger Pedro retires from football
-
Russell hit with Singapore grid penalty for taking new power unit
-
Arteta signs new Arsenal deal until 2030
-
Spotify expands audiobooks to more than 180 markets
-
Stocks decline as oil climbs on Mideast flareup
-
French-Japanese duo wins chemistry Nobel for solving molecular 'mystery'
-
Gauff says online abuse was 'draining' after China Open exit
-
England's Nations League surge helps heal World Cup wounds
-
As sector struggles, Porsche puts luxury ahead of volume
-
Mayor of opposition stronghold Izmir defects to Erdogan party
-
'It's personal': Fiji minister pushes better climate finance at pre-COP
-
Mertens beats Gauff to set up Swiatek clash at China Open
-
Russia glosses over dark Soviet past in reinvented museum
-
Benin full of pride at role in Messi's last dance
-
UK tax body opened probe into Man City in 2018: FT
-
France suspends stun grenade use at student protests ahead of PM speech
-
Yemen's Houthis claim new attacks on Saudi airports as conflict deepens
Spain's BBVA bank to start Sabadell offer Monday
Spanish banking giant BBVA said on Friday its tender offer for smaller national rival Sabadell would start on Monday after its hostile bid received the stock market regulator's green light.
The proposed deal aims to create a European banking powerhouse capable of competing with industry heavyweights such as Santander, BNP Paribas and HSBC.
BBVA, Spain's second-largest bank with a big footprint in Latin America and Turkey, announced its all-share bid in May 2024, valuing Sabadell at around 15 billion euros ($18 billion).
The CNMV stock market regulator ruled that BBVA will have 30 days, beginning on September 8, to get enough Sabadell shareholders to accept the proposal.
"The offer is conditional on the acceptance of a minimum number of shares representing more than half of the voting rights of Banco Sabadell, excluding treasury shares," it said in a statement.
BBVA said its offer is "very attractive", reflecting Sabadell's "best valuation in more than a decade, while incorporating a premium clearly higher than that of recent similar transactions in Europe".
"Following the merger, Banco Sabadell shareholders are set to obtain earnings per share 25 percent higher than they would with a standalone Banco Sabadell," BBVA chair Carlos Torres Vila added in a statement after the CNMV announced its decision.
But Sabadell chairman Josep Oliu hit back, saying his lender had grown more in value, and provided more rewards to its shareholders, than BBVA had since the takeover bid was announced in May 2024.
"It looks like a weak offer based on unrealistic assumptions, but we'll need to analyse it in detail before giving a full opinion," he added in a statement, saying the bid "undervalued our entity's standalone project".
- Hurdles -
Sabadell, Spain's fourth-largest bank, has taken steps to fend off the bid, including the sale of its UK subsidiary TSB to Santander for 3.1 billion euros in what was seen as an effort to weaken its appeal as a takeover target.
Analysts said selling TSB would also give Sabadell more cash for dividends, share buybacks or acquisitions that could reduce the appeal of BBVA's offer to shareholders.
Founded in 1881 near Barcelona, Sabadell has a dispersed ownership structure. No investor holds more than seven percent of the bank, making the outcome of the takeover bid uncertain.
BBVA has already navigated approvals for its offer from the European Central Bank and Spain's competition authority, and overcame opposition from the left-wing Spanish government, which expressed concerns about reduced competition.
Madrid imposed strict conditions in June, requiring a three-year freeze on any merger between the two lenders to safeguard market competition, a move seen as a major roadblock to the deal.
BBVA reported a record net profit of 5.45 billion euros for the first six months of the year, up 9.1 percent from 4.99 billion euros in the same year-ago period.
O.Krause--BTB